Literature DB >> 15980620

Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients.

Terhi Martikainen1, Anna-Maija Teppo, Carola Gronhagen-Riska, Agneta Ekstrand.   

Abstract

BACKGROUND: Glucose absorbed from conventional peritoneal dialysis (PD) solutions contributes to unfavorable metabolic effects. Its replacement with a glucose-free osmotic agent such as icodextrin (ID) or amino acids (AA) may have some benefit on glucose and lipid metabolism.
METHODS: Serum lipids, insulin sensitivity and substrate oxidation (calorimetry) were measured before and after 8 weeks use of ID or AA in 22 patients. Calorimetry and blood tests (HbA1c, lipids) were also performed after 8 weeks of simultaneous use of ID and AA in 8 patients.
RESULTS: Cholesterol declined during the use of AA (4.8 +/- 0.3-4.5 +/- 0.3 mmol/l, p = 0.045). Triglycerides decreased during the use of both ID (2.2 +/- 0.2-1.9 +/- 0.1 mmol/l, p = 0.019) and AA (1.9 +/- 0.2-1.6 +/- 0.1 mmol/l, p = 0.024). Free fatty acids declined during the use of AA. There were no significant changes in insulin sensitivity. Glucose oxidation decreased and lipid oxidation increased during the use of ID, the changes in substrate oxidation were accentuated during the simultaneous use of ID and AA.
CONCLUSION: Replacement of glucose with ID or AA had a benefit on glucose and lipid metabolism. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980620     DOI: 10.1159/000086553

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  12 in total

1.  Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial.

Authors:  Yuji Takatori; Shigeru Akagi; Hitoshi Sugiyama; Junko Inoue; Shoichiro Kojo; Hiroshi Morinaga; Kazushi Nakao; Jun Wada; Hirofumi Makino
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 8.237

2.  Dialysis: low-glucose-containing peritoneal dialysis solutions: good or bad?

Authors:  Vivekanand Jha; Manish Rathi
Journal:  Nat Rev Nephrol       Date:  2013-10-01       Impact factor: 28.314

3.  Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.

Authors:  Yeoungjee Cho; Janine Büchel; Sonja Steppan; Jutta Passlick-Deetjen; Carmel M Hawley; Goce Dimeski; Margaret Clarke; David W Johnson
Journal:  Perit Dial Int       Date:  2015-10-01       Impact factor: 1.756

4.  Incremental peritoneal dialysis allows to reduce the time spent for dialysis, glucose exposure, economic cost, plastic waste and water consumption.

Authors:  Luca Nardelli; Antonio Scalamogna; Elisa Cicero; Giuseppe Castellano
Journal:  J Nephrol       Date:  2022-09-20       Impact factor: 4.393

5.  Biocompatibility of a bicarbonate-buffered amino-acid-based solution for peritoneal dialysis.

Authors:  Thorsten O Bender; Janusz Witowski; Christoph Aufricht; Michaela Endemann; Ulrich Frei; Jutta Passlick-Deetjen; Achim Jörres
Journal:  Pediatr Nephrol       Date:  2008-05-15       Impact factor: 3.714

6.  Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients.

Authors:  Philip K T Li; Bruce F Culleton; Amaury Ariza; Jun-Young Do; David W Johnson; Mauricio Sanabria; Ty R Shockley; Ken Story; Andrey Vatazin; Mauro Verrelli; Alex W Yu; Joanne M Bargman
Journal:  J Am Soc Nephrol       Date:  2013-08-15       Impact factor: 10.121

7.  Biphasic Regulation of Lipid Metabolism: A Meta-Analysis of Icodextrin in Peritoneal Dialysis.

Authors:  Yan-Feng Huang; Da-Jian Zhu; Xiao-Wu Chen; Man-Zhao Ouyang; Wei-Jie Zhang
Journal:  Biomed Res Int       Date:  2015-12-15       Impact factor: 3.411

8.  Future technologies and techniques in peritoneal dialysis-opportunities and challenges ahead.

Authors:  Clifford J Holmes; Watske Smit
Journal:  NDT Plus       Date:  2008-10

9.  Icodextrin does not impact infectious and culture-negative peritonitis rates in peritoneal dialysis patients: a 2-year multicentre, comparative, prospective cohort study.

Authors:  Andreas Vychytil; César Remón; Catherine Michel; Paul Williams; Ana Rodríguez-Carmona; Belén Marrón; Ed Vonesh; Synke van der Heyden; Jose C Divino Filho
Journal:  Nephrol Dial Transplant       Date:  2008-06-13       Impact factor: 5.992

10.  Renal Replacement Therapy: Purifying Efficiency of Automated Peritoneal Dialysis in Diabetic versus Non-Diabetic Patients.

Authors:  Nicanor Vega-Diaz; Fayna Gonzalez-Cabrera; Silvia Marrero-Robayna; Raquel Santana-Estupiñan; Roberto Gallego-Samper; Fernando Henriquez-Palop; Patricia Perez-Borges; José Carlos Rodriguez-Perez
Journal:  J Clin Med       Date:  2015-07-22       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.